Sumesh Kachroo

Sumesh Kachroo

Auto-generated profile, based on publicly available information

Sumesh Kachroo

Affiliation: Merck & Co, Inc., Kenilworth, United States of America

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
JWJohn Waller
John Waller
ESEmma Sullivan
Emma Sullivan
JPJames Piercy
James Piercy
CBChristopher M Black
Christopher M Black
SKSumesh Kachroo
Sumesh Kachroo
Objectives: We examined rheumatologists’ motivation for prescribing biosimilars, assessed their treatment preferences in relation to prescribing behavior and explored patient attitudes to biosimilars. Methods: Data were taken from the Adelphi Real World Biosimilars Programme, a real-world, cross-sectional study undertaken with German rheumatologists and patients with rheumatoid arthritis, ankylosing spondyloarthritis or psoriatic arthritis in 2015–2016. Rheumatologists provided data on their prescribing behavior and attitudes toward biosimilars and invited the next eight eligible consecutive consulting patients to complete a questionnaire. Rheumatologists were split into “investigative”, “conservative” and “other” groups. Results: Overall, 50 rheumatologists and 261 patients participated. Biosimilars accounted for 95% of rheumatologists would prescribe a biooriginator rather than biosimilar as the first- or second-line therapy if unrestricted. Patients showed some reluctance to accept biosimilars, and a small proportion of patients were unhappy when switched from a biooriginator to a biosimilar. Satisfaction with treatment was highest in patients who started treatment with a biooriginator prior to biosimilar availability. Patient concerns when starting treatment with a biooriginator or a biosimilar included not knowing enough about the drug (25%–41%), potential side effects (26%–32%) and potential long-term problems (19%–30%). Conclusion: Study results demonstrate that there is some reluctance from patients to accept biosimilars and the need to educate patients who are unsure to allow them to be involved in decision making, highlighting the importance of patient and physician communication. There remains a need for further research into nonclinical switching and the long-term impact of prescribing biosimilars.

16 January 2016 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
JDJohan Dalén
Johan Dalén
ASAxel Svedbom
Axel Svedbom
CBChristopher M. Black
Christopher M. Black
RLRamon Lyu
Ramon Lyu
QDQian Ding
Qian Ding
SKSumesh Kachroo
Sumesh Kachroo

14 April 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ESEmma Sullivan
Emma Sullivan
JPJames Piercy
James Piercy
JWJohn Waller
John Waller
CBChristopher M Black
Christopher M Black
SKSumesh Kachroo
Sumesh Kachroo
This study examined gastroenterologists’ motivation for prescribing biosimilars, assessed their treatment preferences in relation to prescribing behaviour, and explored patient attitudes to biosimilars. Data were taken from the Adelphi Real World Biosimilars Programme, a real-world, cross-sectional study undertaken in 2015–2016 with German gastroenterologists and patients with ulcerative colitis or Crohn’s disease. Gastroenterologists provided data on their prescribing behaviour and attitudes towards biosimilars, and invited the next eight eligible consecutive consulting patients to complete a detailed questionnaire. For analysis, gastroenterologists were split into ‘Investigative’, ‘Conservative’, and ‘Other’ groups. Overall, 25 gastroenterologists and 136 patients participated. Biosimilars accounted for 80% of gastroenterologists would prescribe a bio-originator rather than biosimilar as 1st line therapy if unrestricted. Patients showed some reluctance to accept biosimilars, although of those receiving biosimilars, 79% were satisfied with the current treatment of their condition, and 69% were satisfied with the control of symptoms. Although at least 35% of patients in each analysis group reported no concerns when starting treatment with a bio-originator or biosimilar, 41% of previously biologic-naïve patients prescribed a biosimilar indicated potential side effects and potential long-term problems, and 24% not knowing enough about the drug, as concerns. Results demonstrate that there is reluctance from patients to accept biosimilars and the need to further educate patients who are unsure to allow them to be involved in decision making, highlighting the importance of patient and physician communication. There remains a need for further research into non-clinical switching and the long term impact of prescribing biosimilars.

5 October 2015 in SpringerPlus
Verified
Journal Article
Open access
PDF file
CBCarl Brown
Carl Brown
PGPeter R. Gibson
Peter R. Gibson
AHAilsa Hart
Ailsa Hart
GKGilaad Kaplan
Gilaad Kaplan
SKSumesh Kachroo
Sumesh Kachroo
KBKathleen Beusterien
Kathleen Beusterien
The objective of this study was to evaluate long-term health-related quality of life outcomes among patients who had a colectomy within the previous 10 years. A cross-sectional survey was administered to consecutive patients ≥18 years of age with ulcerative colitis who had a colectomy within the last 10 years from centers in Canada, Australia, and the United Kingdom. Data were extracted from medical chart reviews to confirm selected self-reported patient characteristics. Of 351 survey respondents, 49 % were male and the median age was 40 years (interquartile range 30–52). Respondents were diagnosed with UC a median of 9.2 (5.7–15.1) years prior to the survey and first surgery occurred a median of 3.7 (2.1–5.8) years ago. Although most respondents (84 %) reported improved quality of life compared to the status before surgery, 81 % experienced problems in at least one of the following areas: depression, work productivity, restrictions in diet, body image, and sexual function. According to HADS scores, 30 and 17 % of survey respondents experienced anxiety and depression, respectively. Among moderate to severe UC patients pre-colectomy, 27 % of men and 28 % of women reported that their sexual life was worse now than before surgery. The mean EQ-5D utility index score overall was 0.79 (95 % confidence interval 0.77–0.81). Quality of life after colectomy for UC is generally good, but there are persistent quality of life issues that impact multiple domains, including psychological and sexual functioning.

28 August 2015 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
RLRamon Lyu
Ramon Lyu
MGMarinella Govoni
Marinella Govoni
QDQian Ding
Qian Ding
CBChristopher M. Black
Christopher M. Black
SKSumesh Kachroo
Sumesh Kachroo
CMCharles Makin
Charles Makin

26 February 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CBChristopher M. Black
Christopher M. Black
EYEric Yu
Eric Yu
EMEilish McCann
Eilish McCann
SKSumesh Kachroo
Sumesh Kachroo
To describe the real-world use of adalimumab for maintenance treatment of ulcerative colitis (UC) and associated healthcare costs in English hospitals. Retrospective cohort study. Analysis of NHS Hospital Episode Statistics linked with pharmacy dispensing data in English hospitals. Adult UC patients receiving ≥240mg during adalimumab treatment induction, subsequently maintained on adalimumab. Frequency and pattern of adalimumab use and dose escalation during maintenance treatment and associated healthcare costs (prescriptions and hospital visits). 191 UC patients completed adalimumab treatment induction. 83 (43.46%) dose escalated during maintenance treatment by ≥100% (equivalent to weekly dosing) (median time to dose escalation: 139 days). 56 patients (67.47%) subsequently de-escalated by ≥50% (median time to dose de-escalation: 21 days). Mean all-cause healthcare costs for all patients ≤12 months of index were £13,892. Dose escalators incurred greater mean healthcare costs than non-escalators ≤12 months of index (£14,596 vs. £13,351). Prescriptions accounted for 96.49% of UC-related healthcare costs (£11,090 of £11,494 in all patients). Within the cohort, 43.46% of UC patients escalated their adalimumab dose by ≥100% and incurred greater costs than non-escalators. The apparent underestimation of adalimumab dose escalation in previous studies may have resulted in underestimated costs in healthcare systems.